

## Genmab

# Key takes FY23: Capital allocation shifts, 1046 PI/II 1H, CD38 data 2H

Reiterate Rating: BUY | PO: 2,540 DKK | Price: 1,878 DKK

## Key takes from the call. Capital, GEN1046, CD38

1) Capital allocation shifts, with focus on later stage BD and introduction of a share buyback (\$500m). Later stage and commercial stage BD to accelerate growth and broaden portfolio. Gmab noted assets need to be best/first in class at minimum, align with current portfolio focus areas, and leverage mid-to-late-stage development and SG&A capabilities. No guardrails on size of deal, but emphasised disciplined evaluation remains. Gmab noted introduction of buyback is sign of confidence on both near term and longer-term value creation or shareholders. 2) GEN1046 to come at conference 1H24 data (early look abstract, as well as longer follow-up). Single PIII start in 2024, though details being finalised with regulators. 4) CD38 hexabody no further PI data from dose expansion cohort presented at ASH. Timings for head to head data confirmed as 2H; 4) 2024 outlook fleshed out: a) Epkinly and Tivdak to contribute c40% of revenue growth (DKK1.2bn), adding to Darzalex growth; b) Opex growth split across i) DKK1.6bn portfolio advancement, namely mid/late stage (Epcore, Tivdak, 1046, 1042) ii) DKK0.3bn Commercialisation on Epkinly DLBCL launch and FL pre-launch in US / JP, as well as pre-launch 1046 , 1042, and TV HNSCC iii) DKK0.2bn SG&A scale.

## Pipeline progress needed vs Darzalex patent debate

We forecast Darzalex loss of royalty from FY29, important given it is c50% of revenues prior to LOE and obviously a larger EBIT contributor. Pipeline progress through FY24 is imperative to build confidence in growth post Darzalex LOE with focus on two assets in particular. Upcoming data (1) CD38 Hexabody; 2) 41BB assets) makes GMAB a “binary” call in FY24 and each asset briefly discussed below.

## CD38 and GEN1046 in greatest focus; Neither slam dunk

1) Genmab presented dose-expansion data at ASH. GMAB previously provided high-level comments on data noting: a) encouraging efficacy, with >VGPR c40% for CD38 (4 out 11 pts) vs Darzalex prior mid-teens (COLUMBA data); b) On safety, noted 2 grade 5 events not deemed treatment related by DSMB; 2) On GEN1046, GMAB has final PII data (2L lung) in house and plans to discuss path forward with regulators.

Estimates (Dec) (DKK)	2022A	2023A	2024E	2025E	2026E
EPS (Adjusted)	84.5	66.6	75.9	108	129
EPS Change (YoY)	83.6%	-21.1%	13.9%	41.9%	19.7%
Dividend / Share	0	0	0	0	0
ADR EPS (Adjusted - US\$)	1.19	0.97	1.09	1.55	1.85
ADR Dividend / Share (US\$)	0	0	0	0	0
<b>Valuation (Dec)</b>					
P/E	22.2x	28.2x	24.7x	17.4x	14.6x
EV / EBITDA*	16.6x	19.6x	18.3x	13.0x	10.9x
Free Cash Flow Yield*	2.93%	5.71%	3.99%	5.61%	6.72%

\* For full definitions of *IQmethod*<sup>SM</sup> measures, see page 6.

15 February 2024

## Equity

### Key Changes

(DKr)	Previous	Current
2024E EPS	76.96	75.88
2025E EPS	97.83	107.70
2026E EPS	125.77	128.89

**Sachin Jain, CFA** >>

Research Analyst  
MLI (UK)  
+44 20 7995 9676  
s.jain@bofa.com

**Graham Parry** >>

Research Analyst  
MLI (UK)  
+44 20 7996 0735  
graham.parry@bofa.com

**Joe Bowden** >>

Research Analyst  
MLI (UK)  
jbowden@bofa.com

**Charlie Haywood** >>

Research Analyst  
MLI (UK)  
charlie.haywood@bofa.com

## Stock Data

Price (Common / ADR)	1,878 DKK / 27.59 USD
Price Objective	2,540 DKK / 37.00 USD
Date Established	18-Jan-2024 / 18-Jan-2024
Investment Opinion	B-1-9 / B-1-9
52-Week Range	1,825 DKK-2,947 DKK
Market Value (mn)	123,959 DKK
Shares Outstanding (mn)	66.0 / 660.2
Average Daily Value (mn)	35.91 USD
Free Float	97.8%
BofA Ticker / Exchange	GNMSF / CPH
BofA Ticker / Exchange	GMAB / NAS
Bloomberg / Reuters	GMAB DC / GMAB.CO
ROE (2024E)	15.3%
Net Dbt to Eqty (Dec-2023A)	-44.9%
ESGMeter <sup>TM</sup>	Medium

ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating. ESGMeter is independent of BofA Global Research's equity investment rating, volatility risk rating, income rating, and price objective for that company. For full details, refer to "BofA ESGMeter Methodology".

>> Employed by a non-US affiliate of BofAS and is not registered/qualified as a research analyst under the FINRA rules.

Refer to "Other Important Disclosures" for information on certain BofA Securities entities that take responsibility for the information herein in particular jurisdictions.

**BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.**

**Refer to important disclosures on page 7 to 10. Analyst Certification on page 5. Price Objective Basis/Risk on page 5.**

12659975

Timestamp: 15 February 2024 04:38AM EST

# iQprofile<sup>SM</sup> Genmab

Key Income Statement Data (Dec)	2022A	2023A	2024E	2025E	2026E
(DKr Millions)					
Sales	14,595	16,474	19,584	24,670	28,360
EBITDA Adjusted	6,573	5,561	5,948	8,390	9,986
Depreciation & Amortization	(216)	(240)	(206)	(227)	(210)
EBIT Adjusted	6,357	5,321	5,742	8,163	9,776
Net Interest & Other Income	678	316	607	711	845
Tax Expense / Benefit	(1,513)	(1,285)	(1,397)	(1,952)	(2,337)
Net Income (Adjusted)	5,522	4,352	4,952	6,922	8,284
Average Fully Diluted Shares Outstanding	66.0	65.9	65.8	64.8	64.8

<b>Key Cash Flow Statement Data</b>					
Net Income (Reported)	5,522	4,352	4,952	6,922	8,284
Depreciation & Amortization	216	240	206	227	210
Change in Working Capital	(1,930)	1,362	(26.1)	(26.3)	(26.6)
Deferred Taxation Charge	0	0	0	0	0
Other CFO	104	1,426	117	0	0
<b>Cash Flow from Operations</b>	<b>3,912</b>	<b>7,380</b>	<b>5,249</b>	<b>7,122</b>	<b>8,468</b>
Capital Expenditure	(317)	(376)	(357)	(357)	(357)
(Acquisition) / Disposal of Investments	(2,405)	(875)	0	0	0
Other CFI	(39.0)	(31.0)	0	0	0
<b>Cash Flow from Investing</b>	<b>(2,761)</b>	<b>(1,282)</b>	<b>(357)</b>	<b>(357)</b>	<b>(357)</b>
Share Issue / (Repurchase)	(908)	(564)	(3,500)	0	0
Cost of Dividends Paid	NA	NA	NA	NA	NA
Increase (decrease) debt	160	157	0	0	0
Other CFF	(41.0)	(199)	0	0	0
<b>Cash Flow from Financing</b>	<b>(789)</b>	<b>(606)</b>	<b>(3,500)</b>	<b>0</b>	<b>0</b>
<b>Total Cash Flow (CFO + CFI + CFF)</b>	<b>362</b>	<b>5,492</b>	<b>1,392</b>	<b>6,765</b>	<b>8,111</b>
FX and other changes to cash	574	(518)	0.05	0	0
Change in Cash	936	4,974	1,392	6,765	8,111
Change in Net Debt	(776)	(4,817)	(1,392)	(6,765)	(8,111)
Net Debt	(9,370)	(14,187)	(15,579)	(22,344)	(30,455)

<b>Key Balance Sheet Data</b>					
Property, Plant & Equipment	799	955	1,161	1,337	1,484
Goodwill	0	0	0	0	0
Other Intangibles	146	101	46.2	0	0
Other Non-Current Assets	956	1,094	1,094	1,094	1,094
Trade Receivables	6,053	5,004	5,054	5,105	5,156
Cash & Equivalents	9,893	14,867	16,259	23,024	31,135
Other Current Assets	12,431	13,268	13,268	13,268	13,268
Total Assets	30,278	35,289	36,882	43,828	52,137
Long-Term Debt	523	680	680	680	680
Other Non-Current Liabilities	491	515	515	515	515
Short-Term Debt	0	0	0	0	0
Other Current Liabilities	1,823	2,484	2,625	2,649	2,674
Total Liabilities	2,837	3,679	3,820	3,844	3,869
Total Equity	27,441	31,610	33,062	39,984	48,268
Total Equity & Liabilities	30,278	35,289	36,882	43,828	52,137

<b>Business Performance*</b>					
Return On Capital Employed	20.4%	15.8%	14.7%	18.2%	18.2%
Return On Equity	22.2%	14.7%	15.3%	19.0%	18.8%
Operating Margin	43.6%	32.3%	29.3%	33.1%	34.5%
Free Cash Flow (MM)	3,595	7,004	4,892	6,765	8,111

<b>Quality of Earnings*</b>					
Cash Realization Ratio	0.71x	1.70x	1.06x	1.03x	1.02x
Asset Replacement Ratio	2.17x	2.03x	2.37x	1.98x	1.70x
Tax Rate	21.5%	22.8%	22.0%	22.0%	22.0%
Net Debt/Equity	-34.1%	-44.9%	-47.1%	-55.9%	-63.1%
Interest Cover	NM	NM	NM	NM	NM

\* For full definitions of iQmethod<sup>SM</sup> measures, see page 6.

## Company Sector

Pharmaceuticals

## Company Description

Genmab is a Danish antibody company that uses its proprietary technology to generate fully human antibodies to disease targets provided by its collaborators. The company receives royalties on Arzerra (ofatumumab, anti-CD-20). Its most exciting asset is Darzalex, anti-CD-38 for multiple myeloma (MM). Darzalex is launched in relapsed MM and is also in the pipeline for earlier lines of therapy and solid tumours. Genmab has a number of partnerships with large biotech/big cap pharma.

## Investment Rationale

Our Buy rating is driven by valuation upside potential and mid-term pipeline upside potential.

## Stock Data

Shares / ADR	0.10
Price to Book Value	3.6x

## Quarterly Earnings Estimates

	2023	2024
Q1	3.46A	9.90E
Q2	20.80A	19.09E
Q3	32.60A	21.21E
Q4	9.88A	25.87E

## Key Changes

(US\$)	Previous	Current
2024E EPS	1.11	1.09
2025E EPS	1.41	1.55
2026E EPS	1.81	1.85

**Exhibit 1: Genmab Sales Model**

sales forecasts

Year to December (DKKm)	YoY Growth %															CAGR 25-28E		
	2022A	2023A	1Q24E	2Q24E	3Q24E	4Q24E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2022A		2023A	2024E
Total Royalties	11,672	13,705	2,856	3,888	4,076	4,900	15,720	17,370	18,668	19,901	21,094	18,234	10,873	5,469	67	17	15	7
Darzalex royalty	10,056	11,265	2,215	3,204	3,327	3,950	12,696	13,643	14,367	15,127	15,925	12,728	5,091	0	64	12	13	5
Kesimpta royalty (MS)	779	1,494	444	482	545	612	2,083	2,634	3,023	3,305	3,480	3,618	3,726	3,261	231	92	39	10
Tepezza royalty	796	704	182	185	186	204	757	832	916	1,007	1,108	1,219	1,316	1,421	34	-12	7	10
Tivdak profit share	332	307	250	250	250	0	750	1,000	1,125	1,250	1,313	1,378	1,447	1,519	1,560	-8	144	9
Total Milestone revenue	1,767	1,177	141	141	141	143	566	1,066	0	0	0	0	0	0	85	-33	-52	-100
Collaboration revenue	338	307	250	250	250	0	750	1,000	1,125	1,250	1,313	1,378	1,447	1,519	1,590	-9	144	9
Total Reimbursement revenue	818	864	255	228	306	161	950	950	950	950	950	950	950	950	54	6	10	0
CD40/41BB	0	0	50	50	100	106	306	714	1,428	2,040	2,448	2,693	2,774	2,801	nm	nm	nm	51
Total Revenues	14,595	16,474	3,752	4,857	5,313	5,662	19,584	24,670	28,360	31,962	34,050	31,837	24,883	19,668	72	13	19	11

Source: Company reports, BofA Global Research estimates

BofA GLOBAL RESEARCH

**Exhibit 2: Genmab Profit & Loss Model**

P/L forecasts

Year to December (DKKmn)	2022A	2023A	1Q24E	2Q24E	3Q24E	4Q24E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	YoY Growth % CAGR			
															2022A	2023A	2024E	25-28E
<b>Revenues</b>	<b>14,595</b>	<b>16,474</b>	<b>3,752</b>	<b>4,857</b>	<b>5,313</b>	<b>5,662</b>	<b>19,584</b>	<b>24,670</b>	<b>28,360</b>	<b>31,962</b>	<b>34,050</b>	<b>31,837</b>	<b>24,883</b>	<b>19,668</b>	72	13	19	11
R&D	-5,562	-7,630	-2,263	-2,409	-2,714	-2,151	-9,538	-11,636	-13,381	-14,719	-16,191	-12,953	-6,476	-1,943	33	37	25	12
% of sales	38.1	46.3	60.3	49.6	51.1	38.0	48.7	47.2	47.2	46.1	47.6	40.7	26.0	9.9				
S,G&A	-2,676	-3,297	-757	-950	-940	-980	-3,627	-3,989	-4,189	-4,398	-4,398	-4,398	-4,398	-4,398	109	23	10	3
% of sales	18.3	20.0	20.2	19.6	17.7	17.3	18.5	16.2	14.8	13.8	12.9	13.8	17.7	22.4				
<b>Operating profit</b>	<b>6,357</b>	<b>5,321</b>	<b>687</b>	<b>1,453</b>	<b>1,614</b>	<b>1,988</b>	<b>5,742</b>	<b>8,163</b>	<b>9,776</b>	<b>11,679</b>	<b>12,271</b>	<b>13,273</b>	<b>12,772</b>	<b>12,065</b>	<b>111</b>	<b>-16</b>	<b>8</b>	<b>15</b>
Margin %	43.6	32.3	18.3	29.9	30.4	35.1	29.3	33.1	34.5	36.5	36.0	41.7	51.3	61.3				
Finance Income	1,358	1,258	152	152	152	152	609	713	847	1,016	1,208	1,417	1,641	1,869	-19	-7	-52	19
Finance Expenses	-680	-942	-1	-1	-1	-1	-2	-2	-2	-2	-2	-2	-2	-2	-3	39	-100	0
<b>Profit before tax</b>	<b>7,035</b>	<b>5,637</b>	<b>838</b>	<b>1,605</b>	<b>1,766</b>	<b>2,139</b>	<b>6,348</b>	<b>8,874</b>	<b>10,621</b>	<b>12,693</b>	<b>13,477</b>	<b>14,688</b>	<b>14,411</b>	<b>13,932</b>	<b>77</b>	<b>-20</b>	<b>13</b>	<b>15</b>
Tax (Expenses) / Income	-1,513	-1,285	-184	-353	-388	-471	-1,397	-1,952	-2,337	-2,792	-2,965	-3,231	-3,170	-3,065	55	-15	9	15
Tax rate %	22	23	22	22	22	22	22	22	22	22	22	22	22	22				
Profit after tax	5,522	4,352	654	1,252	1,377	1,669	4,952	6,922	8,284	9,900	10,512	11,457	11,240	10,867	84	-21	14	15
Margin %	37.8	26.4	17.4	25.8	25.9	29.5	25.3	28.1	29.2	31.0	30.9	36.0	45.2	55.3				
Profit / (Loss) from Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	nm	nm	nm	nm
<b>Net Profit</b>	<b>5,522</b>	<b>4,352</b>	<b>654</b>	<b>1,252</b>	<b>1,377</b>	<b>1,669</b>	<b>4,952</b>	<b>6,922</b>	<b>8,284</b>	<b>9,900</b>	<b>10,512</b>	<b>11,457</b>	<b>11,240</b>	<b>10,867</b>	<b>84</b>	<b>-21</b>	<b>14</b>	<b>15</b>
Margin %	37.8	26.4	17.4	25.8	25.9	29.5	25.3	28.1	29.2	31.0	30.9	36.0	45.2	55.3				
<b>Per share data</b>																		
EPS (core)	84.5	66.6	9.9	19.1	21.2	25.9	75.9	107.7	128.9	154.0	163.6	178.2	174.9	169.1	84	-21	14	15
Basic shares avg	65.4	65.3	66.0	65.6	64.9	64.5	65.3	64.3	64.3	64.3	64.3	64.3	64.3	64.3	-0	-0	-0	0

Source: Company reports, BofA Global Research estimates

BofA GLOBAL RESEARCH

## Price objective basis & risk

### Genmab (GNMSF / GMAB)

Our DKK2540 PO (ADR: US\$37) is DCF-based given expected earnings volatility over the coming years driven by lumpy milestone payments. Assumptions: 1) a discount rate of 8.5% given the focus on lower-risk antibodies and significant portion of the pipeline partnered with big caps: 2) a terminal growth rate of 3%: 3) Individual assets valued based on a sum-of-the-parts.

Upside risks to our PO are increased sales from key assets, increased penetration of biologics, pipeline success (focus on epcoritamab).

Downside risks to our PO are Darzalex commercial execution, clinical trial failure, failure of management to deliver additional partnership deals/progress assets through the pipeline, risk of litigation, adverse currency moves.

## Analyst Certification

I, Sachin Jain, CFA, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

### EMEA - Pharma & Biotech Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	AstraZeneca	AZN	AZN US	Sachin Jain, CFA
	AstraZeneca	AZNCF	AZN LN	Sachin Jain, CFA
	Genmab	GNMSF	GMAB DC	Sachin Jain, CFA
	Genmab	GMAB	GMAB US	Sachin Jain, CFA
	Grifols S.A.	GIFLF	GRF SM	Graham Parry
	Grifols S.A. - B	GRFS	GRFS US	Graham Parry
	Grifols S.A. - B	GIFO	GRF/P SM	Graham Parry
	Lonza AG	LZAGF	LONN SW	Charlie Haywood
	Lonza AG	LZAGY	LZAGY US	Charlie Haywood
	Merck KGaA	MKGAF	MRK GY	Sachin Jain, CFA
	Merck KGaA	MKKGY	MKKGY US	Sachin Jain, CFA
	Novartis	NVSEF	NOVN SW	Graham Parry
	Novartis	NVS	NVS US	Graham Parry
	Novo Nordisk	NONOF	NOVOB DC	Sachin Jain, CFA
	Novo Nordisk	NVO	NVO US	Sachin Jain, CFA
	Sandoz Group AG	SDZXF	SDZ SW	Graham Parry
	Sandoz Group AG	SDZNY	SDZNY US	Graham Parry
	Sanofi	SNYNF	SAN FP	Graham Parry
	Sanofi	SNY	SNY US	Graham Parry
	Sartorius AG	SUVPF	SRT3 GY	Charlie Haywood
<b>NEUTRAL</b>				
	H. Lundbeck A/S	HLUKF	HLUNB DC	Sachin Jain, CFA
	Ipser	IPSEF	IPN FP	Sachin Jain, CFA
	Roche Holdings	RHHBF	ROG SW	Sachin Jain, CFA
	Roche Holdings	RHHBY	RHHBY US	Sachin Jain, CFA
<b>UNDERPERFORM</b>				
	Bayer	BAYZF	BAYN GY	Sachin Jain, CFA
	Bayer	BAYRY	BAYRY US	Sachin Jain, CFA
	GSK Plc	GSK	GSK US	Graham Parry
	GSK Plc	GLAXF	GSK LN	Graham Parry
	Orion	ORINF	ORNBV FH	Graham Parry
	UCB	UCBJF	UCB BB	Graham Parry
	UCB	UCBJY	UCBJY US	Graham Parry



## EMEA - Pharma &amp; Biotech Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
<b>RVW</b>	Idorsia	IDRSF	IDIA SW	Sachin Jain, CFA

**iQmethod<sup>SM</sup> Measures Definitions****Business Performance**

Return On Capital Employed

Return On Equity  
Operating Margin  
Earnings Growth  
Free Cash Flow

**Quality of Earnings**

Cash Realization Ratio  
Asset Replacement Ratio  
Tax Rate  
Net Debt-To-Equity Ratio  
Interest Cover

**Valuation Toolkit**

Price / Earnings Ratio  
Price / Book Value  
Dividend Yield  
Free Cash Flow Yield  
Enterprise Value / Sales

EV / EBITDA

**Numerator**

NOPAT = (EBIT + Interest Income) × (1 – Tax Rate) + Goodwill Amortization

Net Income  
Operating Profit  
Expected 5 Year CAGR From Latest Actual  
Cash Flow From Operations – Total Capex

**Numerator**

Cash Flow From Operations  
Capex  
Tax Charge  
Net Debt = Total Debt – Cash & Equivalents  
EBIT

**Numerator**

Current Share Price  
Current Share Price  
Annualised Declared Cash Dividend  
Cash Flow From Operations – Total Capex  
EV = Current Share Price × Current Shares + Minority Equity + Net Debt +  
Other LT Liabilities  
Enterprise Value

**Denominator**

Total Assets – Current Liabilities + ST Debt + Accumulated Goodwill  
Amortization  
Shareholders' Equity  
Sales  
N/A  
N/A

**Denominator**

Net Income  
Depreciation  
Pre-Tax Income  
Total Equity  
Interest Expense

**Denominator**

Diluted Earnings Per Share (Basis As Specified)  
Shareholders' Equity / Current Basic Shares  
Current Share Price  
Market Cap = Current Share Price × Current Basic Shares  
Sales

Basic EBIT + Depreciation + Amortization

**iQmethod<sup>SM</sup>** is the set of BofA Global Research standard measures that serve to maintain global consistency under three broad headings: Business Performance, Quality of Earnings, and validations. The key features of iQmethod are: A consistently structured, detailed, and transparent methodology. Guidelines to maximize the effectiveness of the comparative valuation process, and to identify some common pitfalls.


**iQdatabase<sup>®</sup>** is our real-time global research database that is sourced directly from our equity analysts' earnings models and includes forecasted as well as historical data for income statements, balance sheets, and cash flow statements for companies covered by BofA Global Research.

**iQprofile<sup>SM</sup>**, **iQmethod<sup>SM</sup>** are service marks of Bank of America Corporation. **iQdatabase<sup>®</sup>** is a registered service mark of Bank of America Corporation.


# Disclosures

## Important Disclosures

### Genmab (GNMSF) Price Chart



### Genmab (GMAB) Price Chart



### Equity Investment Rating Distribution: Health Care Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	234	60.94%	Buy	115	49.15%
Hold	80	20.83%	Hold	36	45.00%
Sell	70	18.23%	Sell	29	41.43%

### Equity Investment Rating Distribution: Global Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships <sup>R1</sup>	Count	Percent
Buy	1895	53.62%	Buy	1083	57.15%
Hold	832	23.54%	Hold	454	54.57%
Sell	807	22.84%	Sell	383	47.46%

<sup>R1</sup> Issuers that were investment banking clients of BofA Securities or one of its affiliates within the past 12 months. For purposes of this Investment Rating Distribution, the coverage universe includes only stocks. A stock rated Neutral is included as a Hold, and a stock rated Underperform is included as a Sell.

**FUNDAMENTAL EQUITY OPINION KEY:** Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. **VOLATILITY RISK RATINGS**, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. **INVESTMENT RATINGS** reflect the analyst's assessment of both a stock's absolute total return potential as well as its attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). Our investment ratings are: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. An investment rating of 6 (No Rating) indicates that a stock is no longer trading on the basis of fundamentals. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating	Total return expectation (within 12-month period of date of initial rating)	Ratings dispersion guidelines for coverage cluster <sup>R2</sup>
Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
Underperform	N/A	≥ 20%

<sup>R2</sup>Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

**INCOME RATINGS**, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. **Coverage Cluster** is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

Price Charts for the securities referenced in this research report are available on the [Price Charts website](#), or call 1-800-MERRILL to have them mailed.

BofAS or one of its affiliates acts as a market maker for the equity securities recommended in the report: Genmab.

The issuer is or was, within the last 12 months, an investment banking client of BofAS and/or one or more of its affiliates: Genmab.

BofAS or an affiliate has received compensation from the issuer for non-investment banking services or products within the past 12 months: Genmab.

The issuer is or was, within the last 12 months, a non-securities business client of BofAS and/or one or more of its affiliates: Genmab.

BofAS or an affiliate has received compensation for investment banking services from this issuer within the past 12 months: Genmab.

BofAS together with its affiliates beneficially owns one percent or more of the common stock of this issuer. If this report was issued on or after the 9th day of the month, it reflects the ownership position on the last day of the previous month. Reports issued before the 9th day of a month reflect the ownership position at the end of the second month preceding the date of the report: Genmab.

BofAS or one of its affiliates is willing to sell to, or buy from, clients the common equity of the issuer on a principal basis: Genmab.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.

## Other Important Disclosures

From time to time research analysts conduct site visits of covered issuers. BofA Global Research policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

Refer to [BofA Global Research policies relating to conflicts of interest](#).

**"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.**

**Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:**

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at [www.bofam.com/BofASEdisclaimer](http://www.bofam.com/BofASEdisclaimer); BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI; BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSF); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Canadian Investment Regulatory Organization; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and



distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSCF; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information prepared and issued by Merrill Lynch (DIFC) is done so in accordance with the requirements of the DFSA conduct of business rules. BofA Europe (Frankfurt) distributes this information in Germany and is regulated by BaFin, the ECB and the CBI. BofA Securities entities, including BofA Europe and BofASE (France), may outsource/delegate the marketing and/or provision of certain research services or aspects of research services to other branches or members of the BofA Securities group. You may be contacted by a different BofA Securities entity acting for and on behalf of your service provider where permitted by applicable law. This does not change your service provider. Please refer to the [Electronic Communications Disclaimers](#) for further information.

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

#### General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities.

This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

#### BofA ESGMeter Methodology:

ESGMeter is a proprietary metric based on quantitative analysis and fundamental analyst inputs that reflects our assessment of a company's Environmental, Social and Governance-related attributes. The ESGMeter is intended to indicate a company's likelihood of experiencing stronger financial stability (higher return on equity and lower earnings and price volatility) over the next three years relative to peer group. There are three ESGMeter levels - Low, Medium, and High - which indicate whether a company has attributes most likely to translate into superior financial stability (in the case of a High level) or weaker financial stability (in the case of a Low level) over the next three years relative to its peer group. A Medium level suggests that a company exhibits ESG characteristics that are likely associated with financial stability results in line with its peer group over the next three years. Full details of our methodology, financial stability definition and disclaimers are available at [BofA ESGMeter methodology](#). ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating.

ESGMeter is independent of the BofA Global Research fundamental equity analyst's investment rating, volatility risk rating, income rating or price objective for that company.

#### Copyright and General Information:

Copyright 2024 Bank of America Corporation. All rights reserved. iQDatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities.

Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Securities in

connection with the legal proceedings or matters relevant to such proceedings.

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS or any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.